Please assess the completion status of the following clinical trial:

Trial Title: Phase 4 Study to Evaluate Treatment Optimization With Once-daily Insulin Glargine 300 U/mL

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria :~* Male or Female.~* Age ≥ 18 years.~* With Type 1 diabetes mellitus.~* Being treated twice-daily with any basal insulin in combination with prandial rapid-acting insulin analogue for at least one year.~* Have an glycated hemoglobin (HbA1c) measurement of 7.5% - 10.0% at study entry.~* Patients who have signed an Informed Consent Form.~Exclusion criteria:~* Type 2 diabetes mellitus.~* Known hypoglycemia unawareness~* Repeated episodes of severe hypoglycemia or diabetes ketoacidosis within the last 12 months.~* End-stage renal failure or being on hemodialysis.~* Any clinically significant abnormality identified on physical examination, laboratory tests, or vital signs at the time of screening or baseline, or any major systemic disease resulting in short life expectancy that in the opinion of the Investigator would restrict or limit the patient's successful participation for the duration of the study.~* Known hypersensitivity / intolerance to insulin glargine or any of its excipients.~* Patients treated with glucagon like peptide agonists.~* Use of systemic glucocorticoids (excluding topical application or inhaled forms) for one week or more within 90 days prior to the time of screening.~* Pregnant or lactating women.~* Women of childbearing potential with no effective contraceptive method.~* Participation in another clinical trial.~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Insulin glargine (U300) (Type: EXPERIMENTAL): Self-administered subcutaneously once daily in the morning, at the same time.The initial dose for patients switching from insulin glargine is 80% of the total daily dose of basal insulin agent that was discontinued. Thereafter, insulin glargine (U300) will follow a titration algorithm for dose adjustment.

Based on this trial design, predict the completion outcome and termination type (if applicable).